Which companies are Lionco Pharmaceutical's closest peers?

The cockpit's peer set: Hunan Hansen Pharmaceutical (002412.SZ), Lanzhou Foci Pharmaceutical (002644.SZ), Hangzhou Minsheng Healthcare (301507.SZ), ABA Chemicals (300261.SZ), CK Life Sciences International (Holdings) (0775.HK), ArriVent BioPharma (AVBP), Shanxi Zhendong Pharmaceutical (300158.SZ), Brother Enterprises (002562.SZ).

Is Lionco Pharmaceutical expensive compared with its peers?

On ev / sales it trades at 10.2× against a peer median of 2.7×, most expensive of 19 in its peer set.

How has Lionco Pharmaceutical stock performed?

Over six months to 6 Nov 2026 the shares returned +21.4% against -23.2% for the median peer; over one year -3.7%.

← CockpitCompetitor Analysis › 603669.SS Lionco Pharmaceutical Group Co., Ltd. Class AOpen in the cockpit ↗

Lionco Pharmaceutical Group Co., Ltd. Class A603669.SSCompetitor analysis, valuation and peers

China · CNY·Health Care›Pharmaceuticals: Other

Momentum leader 84

Competitor Analysis ▸ Charts Open in the cockpit

Mkt cap

$581M

US dollars, full cap

Free float

46%

of shares outstanding

$/day

$36.2M

20-day average traded

Fwd P/E

n/m

no positive forecast

ROIC−WACC

-10.0 pp

WACC 6.3%

Hurdle

n/a

no reverse DCF

Close · CNYCN¥5.44

1D-2.3%

1W+1.5%

1M-18.1%

3M-0.4%

6M+21.4%

YTD+19.3%

1Y-3.7%

ATR %8.0%

52w lowhigh35.2% off high

What Lionco Pharmaceutical does

Employees: 284

Lionco Pharmaceutical at a glance

Size Lionco Pharmaceutical (603669.SS) is a China Health Care company (Pharmaceuticals: Other) with a market value of $581M, the 3499th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥5.44 on 6 Nov 2026.

Performance Over six months the shares gained 21.4%, against -23.2% for the median peer and -16.4% for the China market (cap-weighted) — highest of 21 in its peer set.

Growth Revenue fell 6.2% over the last twelve months (peer median -0.7%); the operating margin is -17.0% (peer median 13.6%).

Valuation It trades at 10.2× enterprise value to sales against a peer median of 2.7× (most expensive of 19).

Capital Return on invested capital runs 10.0 points below its cost of capital (6.3% WACC).

Relative performance

Six months, rebased to 100: Lionco Pharmaceutical against the median of its 20 peers (local-currency closes).

Lionco Pharmaceutical financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
	TTM	FY2025	FY2024	FY2023	FY2022
Revenue	CN¥401M	CN¥322M	CN¥375M	CN¥192M	CN¥283M
Revenue growth	—	-14%	+96%	-32%	—
Gross profit	CN¥196M	CN¥110M	CN¥138M	CN¥45.3M	CN¥150M
EBITDA	n/a	-CN¥71.4M	-CN¥67.0M	-CN¥121M	-CN¥128M
Net income	-CN¥127M	-CN¥193M	-CN¥131M	-CN¥151M	-CN¥196M
Free cash flow	-CN¥43.4M	-CN¥134M	-CN¥102M	-CN¥43.1M	-CN¥86.0M
Capital expenditure	CN¥3.86M	CN¥2.68M	CN¥8.85M	CN¥23.1M	CN¥42.8M
Total debt	CN¥351M	CN¥322M	CN¥280M	CN¥605M	CN¥638M

Quarterly statements and history in the cockpit →

Lionco Pharmaceutical competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

Up and to the right = strong over both horizons. Lionco Pharmaceutical is the large dot.

Fundamentals: revenue growth against valuation

Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Lionco Pharmaceutical is the large dot.

Lionco Pharmaceutical competitors and peer comparison

How Lionco Pharmaceutical compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Lionco Pharmaceutical against its 20 peers (data as of 6 Nov 2026)
Measure	603669.SS	Peer median	Rank in peer set
1-month return	-18.1%	-7.1%	3rd lowest of 21
6-month return	+21.4%	-23.2%	highest of 21
Distance from 52-week high	-35.2%	-40.5%	7th highest of 21
Revenue growth (TTM)	-6.2%	-0.7%	8th lowest of 19
Operating margin	-17.0%	13.6%	3rd lowest of 20
EV / Sales	10.2×	2.7×	most expensive of 19
ROIC minus cost of capital	-10.0 pp	-0.2 pp	3rd lowest of 19

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
Company	Market	Market cap	6M return	Revenue growth	Op. margin	EV / Sales	Req g	Delivered g
Lionco Pharmaceutical 603669.SS	China	$581M	+21%	-6%	-17%	10.2×	n/a	n/a
Hunan Hansen Pharmaceutical 002412.SZ	China	$582M	+10%	-4%	21%	3.4×	3.0%	+7.0%
Lanzhou Foci Pharmaceutical 002644.SZ	China	$582M	-9%	+3%	5%	3.6×	24.3%	+6.5%
Hangzhou Minsheng Healthcare 301507.SZ	China	$624M	-21%	+21%	11%	4.1×	20.4%	+12.1%
ABA Chemicals 300261.SZ	China	$641M	-27%	-16%	-23%	5.2×	n/a	n/a
CK Life Sciences International (Holdings) 0775.HK	Hong Kong	$644M	-30%	0%	0%	2.1×	n/a	n/a
ArriVent BioPharma AVBP	United States	$673M	-54%	n/a	n/a	n/a	n/a	n/a
Shanxi Zhendong Pharmaceutical 300158.SZ	China	$713M	-16%	-28%	-25%	2.0×	n/a	n/a
Brother Enterprises 002562.SZ	China	$716M	-28%	+8%	4%	1.6×	4.9%	+13.5%
China Shineway Pharmaceutical 2877.HK	Hong Kong	$719M	-21%	-18%	25%	n/a	n/a	n/a
Myung in Pharm 317450.KS	South Korea	$455M	-24%	+7%	35%	2.1×	-14.7%	+8.9%
Shanghai Kaibao Pharmaceutical 300039.SZ	China	$756M	-17%	-14%	22%	3.7×	1.8%	+4.8%
Sirio Pharma 300791.SZ	China	$790M	-12%	-9%	1%	1.6×	14.7%	+15.6%
Tibet Aim Pharm 002826.SZ	China	$427M	-23%	+13%	14%	3.1×	1.3%	+1.0%
Tianjin Tianyao Pharmaceuticals 600488.SS	China	$801M	-14%	-12%	3%	2.5×	3.6%	-1.3%
PharmaNutra PHN.MI	Italy	$808M	-18%	+18%	21%	5.1×	4.0%	+18.5%
Boiron BOI.PA	France	$391M	-31%	-2%	5%	0.7×	-0.3%	-0.5%
TSI 603262.SS	China	$909M	-41%	+3%	14%	5.0×	25.8%	+13.4%
Grape King Bio 1707.TW	Taiwan	$361M	-28%	-7%	20%	1.0×	-18.9%	+2.3%
Sihuan Pharmaceutical 0460.HK	Hong Kong	$952M	-35%	+30%	15%	2.3×	n/a	n/a
Daiken Biomedical 7780.TW	Taiwan	$352M	-24%	n/a	18%	3.0×	0.3%	n/a

Questions

Which companies are Lionco Pharmaceutical's closest peers?: The cockpit's peer set: Hunan Hansen Pharmaceutical (002412.SZ), Lanzhou Foci Pharmaceutical (002644.SZ), Hangzhou Minsheng Healthcare (301507.SZ), ABA Chemicals (300261.SZ), CK Life Sciences International (Holdings) (0775.HK), ArriVent BioPharma (AVBP), Shanxi Zhendong Pharmaceutical (300158.SZ), Brother Enterprises (002562.SZ).
Is Lionco Pharmaceutical expensive compared with its peers?: On ev / sales it trades at 10.2× against a peer median of 2.7×, most expensive of 19 in its peer set.
How has Lionco Pharmaceutical stock performed?: Over six months to 6 Nov 2026 the shares returned +21.4% against -23.2% for the median peer; over one year -3.7%.